These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 4215480)

  • 1. Enzyme replacement in Fabry disease: treatment of cultured skin fibroblasts with a purified alpha-galactosidase from ficin.
    Dawson G; Matalon R; Li YT
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):97-101. PubMed ID: 4215480
    [No Abstract]   [Full Text] [Related]  

  • 2. Correction of the enzymic defect in cultured fibroblasts from patients with Fabry's disease: treatment with purified alpha-galactosidase from ficin.
    Dawson G; Matalon R; Li YT
    Pediatr Res; 1973 Aug; 7(8):684-90. PubMed ID: 4732107
    [No Abstract]   [Full Text] [Related]  

  • 3. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease.
    Brady RO; Tallman JF; Johnson WG; Gal AE; Leahy WR; Quirk JM; Dekaban AS
    N Engl J Med; 1973 Jul; 289(1):9-14. PubMed ID: 4196713
    [No Abstract]   [Full Text] [Related]  

  • 4. Enzyme therapy XVII: metabolic and immunologic evaluation of alpha- galactosidase A replacement in Fabry disease.
    Desnick RJ; Dean KJ; Grabowski GA; Bishop DF; Sweeley CC
    Birth Defects Orig Artic Ser; 1980; 16(1):393-413. PubMed ID: 6256019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anderson-Fabry disease.
    Wallace HJ
    Br J Dermatol; 1973 Jan; 88(1):1-23. PubMed ID: 4631337
    [No Abstract]   [Full Text] [Related]  

  • 6. Glycosphingolipids in cultured human skin fibroblasts. II. Characterization and metabolism in fibroblasts from patients with inborn errors of glycosphingolipid and mucopolysaccharide metabolism.
    Dawson G; Matalon R; Dorfman A
    J Biol Chem; 1972 Sep; 247(18):5951-8. PubMed ID: 5057092
    [No Abstract]   [Full Text] [Related]  

  • 7. Glycosphingolipids in cultured human skin fibroblasts. I. Characterization and metabolism in normal fibroblasts.
    Dawson G; Matalon R; Dorfman A
    J Biol Chem; 1972 Sep; 247(18):5944-50. PubMed ID: 5057091
    [No Abstract]   [Full Text] [Related]  

  • 8. Fabry disease: clinical features and recent advances in enzyme replacement therapy.
    Desnick RJ; Wasserstein MP
    Adv Nephrol Necker Hosp; 2001; 31():317-39. PubMed ID: 11692469
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
    Barbey F; Widmer U; Burnier M; Lidove O
    Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudodeficiency of alpha-galactosidase A.
    Bach G; Rosenmann E; Karni A; Cohen T
    Clin Genet; 1982 Jan; 21(1):59-64. PubMed ID: 6279339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fate of internalized alpha-2-macroglobulin: alpha-galactosidase conjugate in fibroblasts from Fabry's hemizygote.
    Osada T; Kuroda Y; Ikai A
    Biochem Biophys Res Commun; 1987 Mar; 143(3):954-8. PubMed ID: 2436620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocytotic internalization of alpha-2-macroglobulin: alpha-galactosidase conjugate by cultured fibroblasts derived from Fabry hemizygote.
    Osada T; Kuroda Y; Ikai A
    Biochem Biophys Res Commun; 1987 Jan; 142(1):100-6. PubMed ID: 2434088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabry disease: kidney transplantation as an enzyme replacement technic.
    Philippart M
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):81-7. PubMed ID: 4215478
    [No Abstract]   [Full Text] [Related]  

  • 14. Endocytosis of lysosomal alpha-galactosidase A by cultured fibroblasts from patients with Fabry disease.
    Mayes JS; Cray EL; Dell VA; Scheerer JB; Sifers RN
    Am J Hum Genet; 1982 Jul; 34(4):602-10. PubMed ID: 6285697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality.
    Yam GH; Roth J; Zuber C
    Biochem Biophys Res Commun; 2007 Aug; 360(2):375-80. PubMed ID: 17592721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Therapy in genetic disease.
    Erbe RW
    N Engl J Med; 1974 Nov; 291(19):1028-9. PubMed ID: 4213051
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzyme replacement in genetic disease. Prospectus.
    Krivit W; Bernlohr RW; Desnick RJ
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):232-3. PubMed ID: 4215476
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
    Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
    Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ConA-mediated binding and uptake of purified alpha-galactosidase A in Fabry fibroblasts.
    Hasholt L; Sørensen SA
    Exp Cell Res; 1983 Oct; 148(2):405-11. PubMed ID: 6313412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical approaches to the nosology of nervous system defects, II.
    Brady RO
    Birth Defects Orig Artic Ser; 1971 Feb; 7(1):33-6. PubMed ID: 4376033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.